Showing results (591-600 of 627) with videos related to

Sort By:
Pageof 63
Biorxiv : the Preprint Server for Biology|June 3, 2024
Human BioMolecular Atlas Program (HuBMAP): 3D Human Reference Atlas Construction and UsageKaty Börner, Philip D Blood, Jonathan C Silverstein, et al.
Urologic Oncology|March 26, 2013
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordanceDavid E Victorson, Penny S Brucker, Rita K Bode, et al.
Nature Methods|March 14, 2025
Human BioMolecular Atlas Program (HuBMAP): 3D Human Reference Atlas construction and usageKaty Börner, Philip D Blood, Jonathan C Silverstein, et al.
Urologic Oncology|May 25, 2025
Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancerManuel R De Jesus Escano, Emily A Vertosick, Neeta D'Souza, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Bladder cancer. Clinical practice guidelines in oncologyJames E Montie, Robert R Bahnson, Samuel M Cohen, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Ontology-based modeling, integration, and analysis of heterogeneous clinical, pathological, and molecular kidney data for precision medicineYongqun Oliver He, Laura Barisoni, Avi Z Rosenberg, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Particle and Fibre Toxicology|December 11, 2025
Sleep disruption from inhalation of biomass smoke: a basis for coincident hypertension?K M Rentschler, W Kyle Martin, W Oshiro, et al.
Leukemia|January 17, 2017
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCTM Neuenhahn, J Albrecht, M Odendahl, et al.
Pageof 63